Table 1.
Key reports on adult soft tissue sarcomas at the 2022 ASCO meeting
| Abstract No. | Regimen | Sarcoma subtype | Treatment line | Patient number | Result |
|---|---|---|---|---|---|
| 11508 | Epirubicine + ifosfamide(EI), trabectedin(T) | MLPS | Neoadjuvant | 101 | AI vs. T: 5 yr-DFS 86% vs. 73%, 5 yr-OS 88% vs. 90% |
| 11575 | Trabectedin | Retroperitoneal LPS or LMS | Post-line | 91 | LMS: ORR 24%, TTP 6 mos; LPS ORR 12%, TTP 6 mos |
| 11507 | Unesbulin (PTC 596), dacarbazine | LMS | Post-line | 33 | ORR 18.2%, RP2D cohort, 5/6 PR |
| 11555 | Regorafenib | LMS, SS, and other STS | Post chemotherapy or pazopanib | 175 | PFS 2.1 mos, OS 14.4 mos |
| 11557 | Surufatinib | LMS, SS, UPS, and other STS | Post-line | 32 | 6 SD, PFS 2.56 mos, 4 mos-PFS 17.5% |
| 11506 | Lenvatinib, eribulin | LPS, LMS | Not specific | 30 | 6 PR, 21 SD, ORR 20%, PFS 8.56 mos, OS 27 mos, 1 yr-OS 89% |
| 3004 | BI 907828 (MDM2-p53 antagonist) | LPS (DDLPS, WDLPS) and other solid tumors with TP53 wild-type | Post-line | 96 (49 LPS) | DDLPS n = 34, 4 PR, ORR 12.5%, DCR 87.5%, PFS 8 mos; WDLPS n = 15, 4 PR, ORR 26.7%, DCR 100%, PFS NR |
| 11509 | Olaparib, temozolomide | Uterine LMS | Post-line | 22 | 6 PR, 9 SD, ORR 27%, DCR 68%, DoR 12 mos, PFS 6.9 mos, OS NR |
| 11503 | Prexasertib (CHK1/2 inhibitor), irinotecan | DSRCT and RMS | Post-line | 21 | DSRCT cohort n = 19, ORR 32%, PFS 24 wks; RMS cohort n = 2 2 SD |
| LBA11501 | Nivolumab, nivolumab + ipilimumab | Retroperitoneal DDLPS, extremity/truncal UPS (with neoadjuvant radiation) | Neoadjuvant | DDLPS 17; UPS 10 | DDLPS cohort: 8.8% hyalinization, RFS 17.5 mos, 2-yr RFS 35%, 2-yr OS 82% UPS cohort: 89% hyalinization, RFS NR, 2 yr-RFS 70%, 2 yr-OS 100% |
| 11573 | Ipilimumab, nivolumab, trabectedin | LMS, LPS, UPS, and others | First-line | 101 | ORR 26.6%, DCR 87.3%, PFS 6.7 mos, OS 24.6 mos |
| 11516 | Gemcitabine, docetaxel, retifanlimab (R) | STS | First-line | 13 | R 270 mg cohort: ORR 17%, DCR 100%, 24 wks-PFS 60%, PFS 24.3 wks; R 375 mg cohort: ORR 50%, DCR 83%, 24 wks-PFS 44%, PFS 22.3 wks |
| 11500 | TCR-T lete-cel; GSK3377794 NY-ESO-1 HLA-A*02:01, *02:05, *02:06 | MRCLS | Post-line | Cohort 1 n = 10; Cohort 2 n = 10 | Cohort 1 (reduced-dose lymphodepletion) n = 10, ORR 20%, DoR 5.31 mos, PFS 5.36 mos; cohort 2 (standard-dose lymphodepletion) n = 10, ORR 40%, DoR 7.47 mos, PFS 8.74 mos |
| 11502 | TCR-T TAEST16001; NY-ESO-1 HLA-A*02:01 | SS (major) and others | Post-line | 12 | 5 PR, 5 SD ORR 41.7%, DoR 14.1 mos, PFS 7.2 mos |
| 11562 | TCR-T Afami-cel; SPEAR T cell MAGE-A4 HLA-A*02 | SS, MRCLS | Post-line | 69 | ORR 36.2%, DoR 52 wks. SS: responders PFS 58.3 wks, 24 wks-PFS 80%; non-responders PFS 11 wks, 24 wks-PFS 20% |
ORR, overall response rate; DoR, duration of response; PFS, progression-free survival; OS, overall survival; MRCLS, myxoid/round cell liposarcoma; SS, synovial sarcoma; LMS, leiomyosarcoma; DDLPS, dedifferentiated liposarcoma; UPS, undifferentiated pleomorphic sarcoma; STS, soft tissue sarcoma; IPI, ipilimumab; LPS, liposarcoma; WDLPS, well-differentiated liposarcoma; RP2D, recommended phase II dose; DSRCT, desmoplastic small round cell tumor; RMS, rhabdomyosarcoma; MLPS, myxoid liposarcoma; TTP, time to progression.